Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04068896 · ClinicalTrials.gov registry record · Phase 1
Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy
A Phase 1 study, sponsored by NGM Biopharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 89
- Enrollment target
NCT04068896 is a Phase 1 study that has completed, run by NGM Biopharmaceuticals. The registered enrollment target is 89 participants.
The verdict
NCT04068896, a Phase 1 study, has completed, sponsored by NGM Biopharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 89 participants
- Enrollment target
Study Summary
Study of NGM120 in subjects with advanced solid tumors and pancreatic cancer (Part 1 and 2) and metastatic castration resistant prostate cancer (Part 3).
Interventions
- BIOLOGICAL NGM120 30mg
- BIOLOGICAL NGM120 100mg
- BIOLOGICAL NGM120 30mg with Gemcitabine and Abraxane
- BIOLOGICAL NGM120 100mg with Gemcitabine and Abraxane
- BIOLOGICAL NGM120 100mg Q3W
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 89 participants |
| Start Date | 2019-10-16 |
| Est. Completion | 2024-01-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04068896
The ClinicalTrials.gov registry entry for NCT04068896 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 89 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NGM Biopharmaceuticals, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which NGM120 30mg is the first listed.
NCT04068896 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04068896 about?
NCT04068896 is a clinical study titled "Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy". Study of NGM120 in subjects with advanced solid tumors and pancreatic cancer (Part 1 and 2) and metastatic castration resistant prostate cancer (Part 3).
What is the current status of trial NCT04068896?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 89 participants. The study started on 2019-10-16. Estimated completion is 2024-01-08.
What interventions are being tested in trial NCT04068896?
The interventions under investigation include: NGM120 30mg (BIOLOGICAL), NGM120 100mg (BIOLOGICAL), NGM120 30mg with Gemcitabine and Abraxane (BIOLOGICAL), NGM120 100mg with Gemcitabine and Abraxane (BIOLOGICAL), NGM120 100mg Q3W (BIOLOGICAL).
Who is sponsoring clinical trial NCT04068896?
This trial is sponsored by NGM Biopharmaceuticals, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.